Active Biotech AB (publ), a biotechnology company, together with its subsidiaries, develops drugs for the treatment of neurodegenerative, inflammatory, and cancer diseases in Sweden. The company is involved in developing ANYARA, a tumor targeting superantigen to kill tumor cell; Tasquinimod, an oral immunomodulatory compound for the treatment of multiple myeloma, a form of blood cancer; and SILC, an S100A9 inhibition by low molecular weight compounds for the treatment of cancer. It is also developing Laquinimod, an oral immunomodulatory drug that has completed Phase II clinical trial for Huntington's disease; and Paquinimod, an oral immunomodulatory compound that has completed Phase I clinical trial for the treatment of systemic lupus erythematosus and systemic sclerosis. The company has a partnership agreement with NeoTX Therapeutics Ltd. for the development of naptumumab. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden.